Nova Eye Medical (ASX:EYE) Research & Development: A$3.17 Mil (TTM As of Dec. 2025)


ASX:EYE Nova Eye Medical Ltd ASX:EYE
55 GF Score
Price A$0.11
GF Value A$0.18
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nova Eye Medical Research & Development?

Nova Eye Medical ASX:EYE +2.44% 55 Research & Development is A$3.17 Mil as of Dec. 2025. GuruFocus rates ASX:EYE with a GF Score™ of 55/100 and a GF Value™ of A$0.18 (Possible Value Trap). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nova Eye Medical's Research & Development for the six months ended in Dec. 2025 was A$1.13 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$3.17 Mil.

Nova Eye Medical  (ASX:EYE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nova Eye Medical Research & Development Related Terms

Nova Eye Medical Research & Development Historical Data

* Premium members only.

The historical data trend for Nova Eye Medical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nova Eye Medical Research & Development Chart

Nova Eye Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.24

Nova Eye Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 1.20 2.04 1.13
ASX:EYE
55GF Score
Nova Eye Medical Ltd ASX:EYE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nova Eye Medical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$3.17 Mil mean?
Nova Eye Medical (ASX:EYE) has a Research & Development of A$3.17 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Nova Eye Medical and its competitors.
Is Nova Eye Medical's Research & Development too high?
Nova Eye Medical's current Research & Development is A$3.17 Mil. Overall, Nova Eye Medical has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's Research & Development compare to ABT and SYK?
Nova Eye Medical's Research & Development of A$3.17 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nova Eye Medical and its competitors. Nova Eye Medical's current Research & Development is A$3.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Based on GuruFocus' analysis, Nova Eye Medical (ASX:EYE) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.18, compared to a current price of A$0.11 — trading 41.7% below its estimated fair value. The current Research & Development is A$3.17 Mil. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nova Eye Medical (ASX:EYE), the current Research & Development is A$3.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nova Eye Medical (ASX:EYE) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued. The current stock price of A$0.11 is trading 41.7% below its estimated GF Value™ of A$0.18. GuruFocus considers Nova Eye Medical to be Possible Value Trap.

Key valuation signals for ASX:EYE:

  • Research & Development: A$3.17 Mil
  • GF Value™: A$0.18 vs. price of A$0.11 (41.7% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the ASX:EYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nova Eye Medical Business Description

Address 107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score

Get the complete analysis for ASX:EYE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.18
GF Value